Search
deferiprone (Ferriprox)
Indications:
- transfusion-related iron overload in patients with thalassemia who do not respond to prior chelation therapy (FDA-approved 10/2011)
Contraindications:
- brain iron chelation with deferiprone associated with worsening of parkinsonism symptoms & adverse events in early Parkinson's disease [2]
Laboratory:
- serum iron
- serum ALT may be elevated
Adverse effects:
- agranulocytosis (2%)
- neutropenia
- nausea
- arthralgia
- vomiting
- chromaturia
- hepatotoxicity ?
Mechanism of action:
- chelating agent
General
chelating agent
References
- FDA NEWS RELEASE: Oct. 14, 2011
FDA approves Ferriprox to treat patients with excess iron in
the body
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
- George J
Brain Iron Chelation Linked With Worse Outcomes in Early Parkinson's.
Findings raise caution about iron chelation in neurodegenerative disorders.
MedPage Today December 2, 2022
https://www.medpagetoday.com/neurology/parkinsonsdisease/102035
- Devos D, Labreuche J, Rascol O et al
Trial of Deferiprone in Parkinson's Disease.
N Engl J Med 2022; 387:2045-2055. Dec 1
PMID: 36449420
https://www.nejm.org/doi/full/10.1056/NEJMoa2209254